5-Amino-1MQ vs Metformin
preclinical vs FDA Approved
monitor Researched · 90% Both affect metabolic pathways; combination may enhance effects but requires careful monitoring.
Molecular Data
5-Amino-1MQ Metformin
Weight — 129.16 Da
Half-life 4-7 hours (3.8h IV, 6.9h oral) ~5 hours
Type Small molecule NNMT enzyme inhibitor Biguanide (C4H11N5)
Key Benefits
5-Amino-1MQ
01 Enhanced NAD+ levels
02 Improved mitochondrial function
03 Better energy metabolism
04 Enhanced cellular repair
05 Improved insulin sensitivity
06 Longevity support
07 Convenient daily oral dosing
Metformin
01 Improved insulin sensitivity and glucose regulation
02 Activation of AMPK, the master metabolic energy sensor
03 Potential lifespan extension and delay of age-related diseases (under investigation in TAME trial)
04 Reduced hepatic glucose output (gluconeogenesis suppression)
05 Modest weight loss or weight neutrality compared to other diabetes medications
06 Anti-inflammatory effects through NF-kB pathway suppression
07 Potential anti-cancer properties via mTOR inhibition and AMPK activation
08 Improved lipid profile with modest reductions in LDL cholesterol and triglycerides
Dosing Protocols
5-Amino-1MQ
50-100mg oral or 150-500mcg SubQ / Once daily, preferably morning
Conservative starting (mcg protocol) 150-250mcg 1x daily
Conservative standard (mcg protocol) 250-500mcg 1x daily
Study-based (mg protocol) ~350mg (5mg/kg) 1x daily
Metformin
500-2000 mg/day / 1-2x daily with meals
Side Effects
5-Amino-1MQ
Generally minimal side effects
Occasional mild GI adjustment
Potential sleep interference if dosed late in day
Metformin
Gastrointestinal distress (nausea, diarrhea, bloating, abdominal cramping) - most frequent complaint, affects up to 25% of users
Metallic taste in mouth
Decreased appetite
Flatulence and abdominal distension
Loose stools, particularly when initiating therapy or increasing dose
Contraindications
Pregnancy or breastfeeding
Pre-existing metabolic conditions (consult healthcare provider)
Severe renal impairment (eGFR below 30 mL/min/1.73m2)
Acute or chronic metabolic acidosis, including diabetic ketoacidosis
Known hypersensitivity to metformin
Acute conditions with potential for tissue hypoxia (decompensated heart failure, respiratory failure, recent MI, sepsis)
Severe hepatic impairment
Excessive alcohol intake (increases risk of lactic acidosis)
Research Evidence
5-Amino-1MQ Metformin
Status preclinical FDA Approved
References 3 studies 5 studies
Latest August 2024 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.